Chungsoo Kim

Employment

• Ajou University Assistant Professor
  2026 - Present
• Yale University Postdoctoral Associate
  2024 - 2026

Education

• Ajou University PhD in Biomedical Informatics
  2019 - 2024
• Ajou University PharmD
  2015 - 2019

Projects & Funding

Projects & funding information is unavailable.

Publications (90)

• Missed Opportunities for Stroke Prevention in Patients With Hypertension: A Retrospective Case–Control Study
  Journal of the American Heart Association 2026 DOI: 10.1161/JAHA.126.051284
  +Save
• Glucagon‐Like Peptide‐1 Receptor Agonists and Risk of Mental Health Disorders in Type 2 Diabetes: Active Comparator, New User Cohort Study
  Diabetes, Obesity and Metabolism 2026 DOI: 10.1111/dom.70985
  +Save
• Single-Pill Combination Therapy for Hypertension
  JACC 2026 DOI: 10.1016/j.jacc.2026.03.088
  +Save
• Target trial emulation of survival outcomes for clinically localized prostate cancer treatments
  Discover Oncology 2026 DOI: 10.1007/s12672-026-05392-4
  +Save
• Comparative Cardiovascular Effectiveness of Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors in Diabetes Mellitus
  JACC 2026 DOI: 10.1016/j.jacc.2026.02.5123
  +Save
• Sex Differences in Comparative Effectiveness and Safety of Second-line Antidiabetic Agents: Real-world Evidence from Large-scale Multinational Study
  2026 DOI: 10.64898/2026.04.10.26350252
  +Save
• Real-world evidence for comparative safety of second-line antihyperglycemic agents in older adults with type 2 diabetes
  Nature Communications 2026 DOI: 10.1038/s41467-026-71307-0
  +Save
• Comparative Cardiovascular Effectiveness of Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors in Diabetes Mellitus
  2026 DOI: 10.64898/2026.02.23.26346890
  +Save
• GLP-1 Receptor Agonist Prescriptions for Adolescents With Obesity and Associated Disparities
  JAMA PEDIATRICS 2026 DOI: 10.1001/JAMAPEDIATRICS.2025.5708
  +Save
• Semaglutide and Tirzepatide Prescribing for Obesity in Patients With Preexisting Comorbid Cancers
  JAMA ONCOLOGY 2026 DOI: 10.1001/JAMAONCOL.2025.4560
  +Save
• Data Resource Profile: Health Insurance Review and Assessment Service Korean Nationwide Claims OMOP-CDM (2015–2024) database, “HIRA K-OMOP”
  2025 DOI: 10.64898/2025.12.08.25341603
  +Save
• Prescribing of GLP-1 Receptor Agonists for Adolescents with Obesity and Associated Disparities
  2025 DOI: 10.1101/2025.10.06.25337411
  +Save
• Association Between Neighborhood-Level Social Vulnerability and Hypertension Outcomes
  JACC: Advances 2025 DOI: 10.1016/j.jacadv.2025.101912
  +Save
• Survival Outcomes after Monitoring, Surgery, or Radiotherapy for Clinically Localized Prostate Cancer
  2025 DOI: 10.1101/2025.07.16.25331661
  +Save
• Impact of Regulatory Post‐Market Safety Advisories on Prescribing Practices: An Interrupted Time Series Analysis
  Clinical Pharmacology & Therapeutics 2025 DOI: 10.1002/cpt.3614
  +Save
• Renal and Safety Outcomes of SGLT2 Inhibitors in Patients with Type 2 Diabetes: A Nationwide Observational Cohort Study
  Journal of Clinical Medicine 2025 DOI: 10.3390/jcm14103349
  +Save
• Comparative Safety of Second-Line Antihyperglycemic Agents in Older Adults with Type 2 Diabetes: A Multinational Real-World Evidence From LEGEND-T2DM
  2025 DOI: 10.1101/2025.05.08.25327248
  +Save
• Risk of aortic aneurysm or dissection following use of fluoroquinolones: a retrospective multinational network cohort study
  eClinicalMedicine 2025 DOI: 10.1016/j.eclinm.2025.103096
  +Save
• A failure to launch: blood pressure control after stroke in a regional health system
  JOURNAL OF HYPERTENSION 2025 DOI: 10.1097/HJH.0000000000003961
  +Save
• Abstract 4367801: Tirzepatide Achieves Greater Weight and Blood Pressure Reduction Than Semaglutide in Routine Clinical Practice
  CIRCULATION 2025 DOI: 10.1161/CIRC.152.SUPPL_3.4367801
  +Save